Literature DB >> 19128507

Severe cutaneous toxicity following treatment with radiotherapy and cetuximab: a case report.

Arun Azad1.   

Abstract

While the addition of cetuximab to radiotherapy improves clinical outcomes in locoregionally advanced head and neck squamous cell cancers, there are a small number of reports of severe radiation dermatitis occurring with this therapeutic combination. We present the case of a 69 year old male who developed severe radiation dermatitis following treatment with cetuximab and radiotherapy for a locoregionally advanced head and neck squamous cell cancer.

Entities:  

Year:  2009        PMID： 19128507      PMCID： PMC2628867          DOI： 10.1186/1757-1626-2-25

Source DB:  PubMed          Journal:  Cases J        ISSN： 1757-1626


  8 in total

1.  Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.

Authors:  W Jacot; D Bessis; E Jorda; M Ychou; M Fabbro; J-L Pujol; B Guillot
Journal:  Br J Dermatol       Date:  2004-07       Impact factor: 9.302

2.  Severe cutaneous reaction during radiation therapy with concurrent cetuximab.

Authors:  Wilfried Budach; Edwin Bölke; Bernhard Homey
Journal:  N Engl J Med       Date:  2007-08-02       Impact factor: 91.245

3.  Acneiform rash secondary to cetuximab plus head and neck radiotherapy.

Authors:  Aminudin Rahman Mydin; John G Armstrong
Journal:  Radiother Oncol       Date:  2007-05-24       Impact factor: 6.280

4.  Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.

Authors:  K J Busam; P Capodieci; R Motzer; T Kiehn; D Phelan; A C Halpern
Journal:  Br J Dermatol       Date:  2001-06       Impact factor: 9.302

5.  Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.

Authors:  J R Grandis; D J Tweardy
Journal:  Cancer Res       Date:  1993-08-01       Impact factor: 12.701

6.  Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.

Authors:  J Bernier; J Bonner; J B Vermorken; R-J Bensadoun; R Dummer; J Giralt; G Kornek; A Hartley; R Mesia; C Robert; S Segaert; K K Ang
Journal:  Ann Oncol       Date:  2007-09-04       Impact factor: 32.976

7.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

8.  Severe skin reaction secondary to concomitant radiotherapy plus cetuximab.

Authors:  Bernhard Berger; Claus Belka
Journal:  Radiat Oncol       Date:  2008-01-28       Impact factor: 3.481
  8 in total
  4 in total

1.  Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab.

Authors:  Edgar Selzer; Susanne Liederer; Christiane Lemaire; Gerhard Kren; Dejan Radonjic; Gabriela Kornek; Thomas Knocke; Richard Pötter; Barbara Bachtiary
Journal:  Strahlenther Onkol       Date:  2011-05-16       Impact factor: 3.621

2.  Acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with concurrent cetuximab and radiotherapy.

Authors:  M Valeriani; R Muni; M F Osti; V De Sanctis; G Minniti; F Ardito; R Maurizi Enrici
Journal:  Radiol Med       Date:  2011-09-02       Impact factor: 3.469

3.  Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer.

Authors:  M Fakih; M Vincent
Journal:  Curr Oncol       Date:  2010-07       Impact factor: 3.677

4.  Cetuximab: its unique place in head and neck cancer treatment.

Authors:  Pol Specenier; Jan B Vermorken
Journal:  Biologics       Date:  2013-04-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.